Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00966277 · ClinicalTrials.gov registry record · Phase 4
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
A Phase 4 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 87
- Enrollment target
NCT00966277: Completed Phase 4 study, sponsored by M.D. Anderson Cancer Center.
NCT00966277 is a Phase 4 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 87 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00966277, a Phase 4 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 87 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if dalteparin can lower the risk of VTE occurring in the legs and lungs. This will be tested in patients with pancreatic cancer who are going to receive chemotherapy. Some patients will receive dalteparin and some will receive no study drug. The safety of dalteparin will also be studied.
Interventions
- DRUG Dalteparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00966277
The ClinicalTrials.gov registry entry for NCT00966277 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dalteparin is the first listed.
NCT00966277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00966277 about?
NCT00966277 is a clinical study titled "Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients". The goal of this clinical research study is to learn if dalteparin can lower the risk of VTE occurring in the legs and lungs. This will be tested in patients with pancreatic cancer who are going to receive chemotherapy. Some patients will receive dalteparin and some will receive no study drug. The ...
What is the current status of trial NCT00966277?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 87 participants. The study started on 2010-04. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00966277?
The interventions under investigation include: Dalteparin (DRUG).
Who is sponsoring clinical trial NCT00966277?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.